Migraine is linked to high medical costs. However, recent estimates of the economic burden by type of migraine are lacking. A study presented at AMCP Nexus 2021 estimated the annual incremental costs associated with migraines overall, episodic migraine (EM), and chronic migraine (CM).
This retrospective claim analysis consisted of 465,765 continuously eligible, commercially insured individuals aged between 18-64 years. Of the population of interest, 90,017 had migraine (EM, 66,896 patients; CM, 23,121 patients) and 375,748 were non-migraine controls. The investigators used linear models to estimate the incremental adjusted all-cause costs of the three migraine groups.
According to the findings, compared with controls, the overall migraine group had appreciably higher all-cause total ($22,995 vs. $8,485), medical ($19,231 vs. $6,624), and prescription ($3,764 vs. $1,861) costs (all P<0.0001). Patients with EM and CM had notably higher all-cause total ($22,150 and $25,441, respectively), medical ($18,943 and $20,065), and prescription ($3,207 and $5,377) costs compared with controls (all P<0.0001).
The researchers noted that most of the differences in total costs were attributable to the incremental adjusted medical costs of the overall migraine (+$5,166), EM (+$4,744), and CM groups (+$6,388) versus controls (all P<0.0001).
“Patients with overall migraine and by type of migraine (EM and CM) have significantly higher total, medical, and prescription costs relative to non-migraine controls,” the researchers concluded.
Source: Joshi S, et al. G34 The Economic Burden of Migraine Estimated by Type of Migraine. Poster G34. Published for AMCP Nexus 2021; October 18-21, 2021, Denver, CO.